Gain Accounts Payable vs Common Stock Analysis

GANX Stock  USD 1.86  0.12  6.90%   
Gain Therapeutics financial indicator trend analysis is much more than just examining Gain Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gain Therapeutics is a good investment. Please check the relationship between Gain Therapeutics Accounts Payable and its Common Stock accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.

Accounts Payable vs Common Stock

Accounts Payable vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gain Therapeutics Accounts Payable account and Common Stock. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Gain Therapeutics' Accounts Payable and Common Stock is 0.85. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Common Stock in the same time period over historical financial statements of Gain Therapeutics, assuming nothing else is changed. The correlation between historical values of Gain Therapeutics' Accounts Payable and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Gain Therapeutics are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Accounts Payable i.e., Gain Therapeutics' Accounts Payable and Common Stock go up and down completely randomly.

Correlation Coefficient

0.85
Relationship DirectionPositive 
Relationship StrengthStrong

Accounts Payable

An accounting item on the balance sheet that represents Gain Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Gain Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Common Stock

Most indicators from Gain Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gain Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.At this time, Gain Therapeutics' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 11.3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3 M in 2024.
 2021 2022 2023 2024 (projected)
Reconciled Depreciation15.5K64.2K78.1K82.0K
Total Operating Expenses14.0M17.9M22.3M11.2M

Gain Therapeutics fundamental ratios Correlations

1.00.740.84-0.90.950.850.80.820.850.970.80.97-0.020.810.830.760.830.37-0.580.60.820.850.790.920.81
1.00.740.82-0.910.950.860.820.840.860.960.770.96-0.030.790.830.730.810.42-0.560.580.770.860.770.910.81
0.740.740.92-0.640.650.860.630.820.650.820.930.790.530.920.920.920.920.21-0.90.910.60.860.930.80.93
0.840.820.92-0.720.710.820.670.680.730.930.990.910.480.980.90.970.950.22-0.920.930.70.830.990.880.9
-0.9-0.91-0.64-0.72-0.82-0.71-0.97-0.76-0.99-0.89-0.67-0.90.2-0.71-0.71-0.65-0.72-0.710.49-0.53-0.67-0.74-0.69-0.95-0.71
0.950.950.650.71-0.820.870.70.820.750.860.680.85-0.10.710.820.650.780.26-0.420.450.850.870.670.820.79
0.850.860.860.82-0.710.870.670.830.680.830.820.810.330.820.960.780.880.24-0.70.720.660.990.80.790.96
0.80.820.630.67-0.970.70.670.710.990.810.630.83-0.140.660.670.610.660.83-0.520.550.490.710.650.910.68
0.820.840.820.68-0.760.820.830.710.710.780.660.750.020.680.790.630.730.37-0.510.540.620.840.660.760.79
0.850.860.650.73-0.990.750.680.990.710.860.680.88-0.140.720.70.670.710.76-0.540.580.60.720.710.950.7
0.970.960.820.93-0.890.860.830.810.780.860.891.00.140.890.850.850.880.39-0.720.740.760.830.880.950.84
0.80.770.930.99-0.670.680.820.630.660.680.890.860.531.00.921.00.980.16-0.940.950.730.831.00.860.92
0.970.960.790.91-0.90.850.810.830.750.881.00.860.110.870.820.830.850.44-0.710.720.730.810.860.950.81
-0.02-0.030.530.480.2-0.10.33-0.140.02-0.140.140.530.110.480.430.530.44-0.34-0.730.71-0.020.310.510.070.46
0.810.790.920.98-0.710.710.820.660.680.720.891.00.870.480.931.00.990.19-0.920.930.760.841.00.890.93
0.830.830.920.9-0.710.820.960.670.790.70.850.920.820.430.930.910.980.19-0.820.840.750.970.920.851.0
0.760.730.920.97-0.650.650.780.610.630.670.851.00.830.531.00.910.980.14-0.940.950.730.81.00.860.91
0.830.810.920.95-0.720.780.880.660.730.710.880.980.850.440.990.980.980.16-0.870.890.810.90.980.890.96
0.370.420.210.22-0.710.260.240.830.370.760.390.160.44-0.340.190.190.140.16-0.160.18-0.030.280.20.540.23
-0.58-0.56-0.9-0.920.49-0.42-0.7-0.52-0.51-0.54-0.72-0.94-0.71-0.73-0.92-0.82-0.94-0.87-0.16-1.0-0.47-0.71-0.94-0.72-0.84
0.60.580.910.93-0.530.450.720.550.540.580.740.950.720.710.930.840.950.890.18-1.00.490.730.950.750.86
0.820.770.60.7-0.670.850.660.490.620.60.760.730.73-0.020.760.750.730.81-0.03-0.470.490.690.730.760.69
0.850.860.860.83-0.740.870.990.710.840.720.830.830.810.310.840.970.80.90.28-0.710.730.690.820.830.97
0.790.770.930.99-0.690.670.80.650.660.710.881.00.860.511.00.921.00.980.2-0.940.950.730.820.880.92
0.920.910.80.88-0.950.820.790.910.760.950.950.860.950.070.890.850.860.890.54-0.720.750.760.830.880.84
0.810.810.930.9-0.710.790.960.680.790.70.840.920.810.460.931.00.910.960.23-0.840.860.690.970.920.84
Click cells to compare fundamentals

Gain Therapeutics Account Relationship Matchups

Gain Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Other Current Liab253.7K767.4K1.2M2.0M2.1M1.2M
Total Current Liabilities879.1K2.1M2.6M4.1M4.9M2.8M
Other Liab132.2K171.6K329.5K157.6K181.2K179.3K
Net Tangible Assets(450.0K)6.2M34.6M18.7M21.5M12.8M
Retained Earnings(3.5M)(7.0M)(20.9M)(38.5M)(60.8M)(57.7M)
Accounts Payable154.4K961.5K560.5K1.6M1.3M874.7K
Other Assets11.4K63.8K53.4K48.3K55.6K41.4K
Net Receivables44.9K66.6K113.6K103.9K242.6K254.7K
Other Current Assets49.8K71.0K343.1K399.8K741.6K778.7K
Other Stockholder Equity3.1M13.4M55.8M57.4M73.1M37.2M
Total Current Assets429.5K9.0M37.7M21.1M17.8M15.9M
Property Plant Equipment219.3K552.7K1.0M144.4K166.0K157.7K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Gain Stock Analysis

When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.